Vanguard Asset Management’s LB Pharmaceuticals LBRX Stock Holding History

Vanguard Asset Management’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$342K	Buy	+10,540	New	+$310K	﹤0.01%	2309

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Vanguard Asset Management's LBRX Position: Q2 2026 in Review

Vanguard Asset Management opened a new position in LB Pharmaceuticals (LBRX) in Q2 2026: 10,540 shares worth $342K. The stake represents ﹤0.01% of the portfolio and ranks #2309 among its holdings.

106 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

Vanguard Asset Management held 10,540 shares of LB Pharmaceuticals worth $342K as of Q2 2026.
LB Pharmaceuticals was a new Vanguard Asset Management position in Q2 2026.
LB Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2309 holding.
106 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.